All Insights

Most AI inference runs through three cloud providers and one or two chip manufacturers — a single point of failure smaller than a mid-sized corporate IT department, for the entire global AI stack. Why AI dominance is no longer the real question, and what building resilience around it actually requires.

A hospital running AI-assisted radiology for a decade doesn't have the radiologists to revert — they were never hired, never trained. Why the fallback to pre-AI operation isn't a step backward in time for the most dependent industries. It's a step off a cliff.

AI has quietly become the third layer of critical infrastructure, after power and internet — but unlike those systems, it has no equivalent resilience standards, regulatory oversight, or stress-testing. A sector-by-sector risk map of what breaks first, and why the fallback keeps disappearing.

SMMT's 5-year bull case reaches 500-1000% — but carries a real scenario of losing nearly everything. LLY, despite an 800% run since 2019, now trades at 38x earnings with a base case barely ahead of the S&P 500. A side-by-side scenario analysis across three completely different risk profiles.

A tech company's marginal cost of serving one more customer is fractions of a penny. A pharma company's cost scales with every pill manufactured, shipped, and monitored. That single structural difference explains more of the tech-pharma performance gap than any other factor — and it's not the whole story.

Institutional-quality pharma research requires no Bloomberg terminal — it requires knowing that FDA Medical Reviews, R&D Day slide decks, and ClinicalTrials.gov protocols exist, and reading them critically. A complete map of every public source serious pharma investors use, and a step-by-step research workflow you can apply to any company.

Pascal Soriot rejected an 87 billion euro takeover bid in 2014, betting the company's future on a single compound that became Tagrisso. David Ricks calls his leadership approach "bumpers on the bowling alley." Eight pharma CEOs, profiled by leadership archetype — and why matching the right archetype to the right strategic moment matters more than any individual decision.

Lilly's retatruitide hit 29% weight loss in Phase 2 — the highest ever recorded for an obesity drug — while AstraZeneca built the deepest ADC oncology platform through a Daiichi Sankyo partnership. Eight mega-cap pharma pipelines, ranked by which companies are building genuine scientific moats versus catching up from behind.

Biotech ETFs have underperformed the S&P 500 over both 5- and 10-year periods, with far more volatility — yet the sector still produces 3-20x returns for selective investors. Five distinct return mechanisms explain the paradox, ranked from accessible to non-scientists (M&A basket positioning) to requiring genuine scientific literacy (platform discount investing).

ARKG surged 185% in 2020, then fell 75% peak-to-trough — the most dramatic boom-bust cycle among the four major biotech ETFs. A composition and returns breakdown of XBI, IBB, ARKG, and BBH, mapped to which investor profile each one actually fits.